ResMed Inc.RMDNYSE

Overview Intelligence Charts News Fundamentals DCF Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

24 analysts·High coverage

54%

Rating Distribution

Strong Buy

00%

Buy

1354%

Hold

938%

Sell

28%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 16% higher.

Bear Case

$265.00

+4%

Consensus

$295.88

+16%

Bull Case

$345.00

+35%

Price Range24 analysts

Low

Consensus

High

$265.00

$345.00

Current Target

Current Price

$255.82

Upside to Target

$40.06

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$11.06(13 analysts)

P/E25x

Current: 25.3x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+7.46%

EPS+11.00%

FY2028

Rev+6.88%

EPS+9.42%

FY2029

Rev+7.92%

EPS+7.37%

Earnings Surprises

Beat rate:67%(8/12 quarters)

Avg surprise:+2.8%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 30, 2026RBC Capital

ResMed price target raised to $314 from $311 at RBC Capital

Target:$314.00

+23.6%from $254.08

Jan 30, 2026Stifel Nicolaus

ResMed price target raised to $265 from $260 at Stifel

Target:$265.00

+2.9%from $257.61

Jan 30, 2026KeyBanc

ResMed price target raised to $302 from $299 at KeyBanc

Target:$302.00

+17.2%from $257.61

Jan 30, 2026Robert W. Baird

ResMed price target raised to $281 from $275 at Baird

Target:$281.00

+9.1%from $257.61

Jan 30, 2026Piper Sandler

ResMed price target raised to $275 from $270 at Piper Sandler

Target:$275.00

+6.8%from $257.61

Dec 18, 2025Stifel Nicolaus

ResMed (RMD) PT Lowered to $260 at Stifel

Target:$260.00

+5.7%from $245.94

Dec 16, 2025Robert W. Baird

ResMed downgraded to Neutral from Outperform at Baird

Target:$275.00

+8.7%from $253.07

Dec 12, 2025UBS

ResMed (RMD) PT Raised to $345 at UBS

Target:$345.00

+37.2%from $251.38

Nov 3, 2025Robert W. Baird

ResMed price target lowered to $300 from $320 at Baird

Target:$300.00

+21.5%from $246.88

Oct 31, 2025KeyBanc

ResMed price target raised to $299 from $298 at KeyBanc

Target:$299.00

+22.5%from $244.12

Oct 31, 2025Morgan Stanley

ResMed price target raised to $305 from $304 at Morgan Stanley

Target:$305.00

+20.9%from $252.26

Oct 21, 2025Morgan Stanley

ResMed price target raised to $304 from $298 at Morgan Stanley

Target:$304.00

+12.0%from $271.41

Oct 13, 2025Wells Fargo

ResMed initiated with an Equal Weight at Wells Fargo

Target:$280.00

+2.9%from $272.00

May 20, 2025Morgan Stanley

Morgan Stanley sees 'modest' earnings impact to ResMed from Apnimed

Target:$286.00

+15.3%from $248.14

Apr 24, 2025KeyBanc

ResMed price target raised to $274 from $269 at KeyBanc

Target:$274.00

+17.8%from $232.65

Apr 16, 2025Mizuho Securities

ResMed price target lowered to $265 from $280 at Mizuho

Target:$265.00

+25.3%from $211.49

Mar 5, 2025Stifel Nicolaus

ResMed price target lowered to $240 from $250 at Stifel

Target:$240.00

+7.2%from $223.83

Jan 31, 2025Piper Sandler

ResMed price target raised to $260 from $252 at Piper Sandler

Target:$260.00

+10.1%from $236.18

Dec 12, 2024Stifel Nicolaus

ResMed initiated with a Hold at Stifel

Target:$250.00

+3.1%from $242.51

Oct 1, 2024RBC Capital

ResMed (RMD) PT Raised to $224 at RBC Capital

Target:$224.00

-6.3%from $238.95

Sep 23, 2024Robert W. Baird

Baird Starts ResMed (RMD) at Outperform

Target:$280.00

+13.7%from $246.18

Sep 18, 2024Wolfe Research

Wolfe Research Downgrades ResMed (RMD) to Underperform

Target:$180.00

-28.3%from $250.88

Apr 10, 2024RBC Capital

ResMed (RMD) PT Raised to $187 at RBC Capital

Target:$187.00

-3.7%from $194.27

Apr 1, 2024Stifel Nicolaus

ResMed (RMD) PT Raised to $224 at Stifel

Target:$224.00

+13.1%from $198.03

Oct 27, 2023Oppenheimer

How Sleep Device Player ResMed Is Gaining Philips' Market Share In Flow Generator Market - Analysts Weigh In

Target:$175.00

+30.0%from $134.65

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance